Newsroom

BioSpace | Clinical Catch-Up: January 3-7

Mark Terry January 10, 2022 https://www.biospace.com/article/-clinical-catch-up-january-3-7 The biopharma industry has started 2022 with...

Biotech 2050 Podcast | Hong Tang on Biotech in 2022

BioSpace | Biopharma Executive Perspectives on 2022

Heather McKenzie January 10, 2022 https://www.biospace.com/article/executive-perspectives-on-2022-/ After a decade of breakthroughs in...

Targeted Oncology | OQL011 for Hand and Foot Reaction Shows Clinical Activity, Tolerable Safety

By Sara Karlovitch OQL011, for cancer therapy induced skin toxicity, demonstrated a tolerable safety and acceptable efficacy profile,...

OnQuality Pharmaceuticals Reports Topline Data from Phase 2 Trial of Treatment for Cancer [...]

Therapy Induced Skin Toxicity that Met Expectations - Part 1 of the Phase 2 NOVA-II clinical trial evaluating OQL011 met the company's...

HealthBiz I Interview with OnQuality co-founder Dr. Hong Tang

David E. Williams November 11, 2021 Hong Tang grew up in rural China, and was encouraged by her pharmacist sister to become a physician....

NPR BioTech Nation I Episode 21-46 Neuroscience and Dreaming

Moira Gunn November 9 On this week’s Tech Nation, Moira speaks with Dr. Sidarta Ribeiro, Deputy Director of the Brain Institute at the...

GEN | 40th Anniversary Recollections & Predictions

To help celebrate GEN’s 40th Anniversary with this special October issue, we asked scientists and business professionals in academia and...

Targeted Oncology | Skin Toxicity in Cancer Treatment: A Critical Part of Cancer Supportive Care

In contrast to the innovations in cancer treatments that help drive improved survival, there are far fewer innovations targeting...

OnQuality Pharmaceuticals Announces Completion of Part 1 of NOVA-II Trial

- Top-line readout of clinical study results anticipated by the end of 2021 SEATTLE, Sept. 7, 2021 /PRNewswire/ -- OnQuality...